Notice 14 March 2025: Supply Constraints with Docetaxel 200mg/ml Injection 1ml for Oncology Treatment and Interim Therapeutic Alternatives
The Tertiary and Quaternary Essential Medicines List (EML) currently recommends the use of a taxanes (paclitaxel or docetaxel) for the management of various cancers including breast, prostate and lung. Docetaxel 20mg/ml, 1ml injection, which is on National Contract from Accord Healthcare (Pty) Ltd, is currently unavailable. The docetaxel 20mg injection, will only be available at the end of April
The Tertiary and Quaternary Essential Medicines List (EML) currently recommends the use of a taxanes (paclitaxel or docetaxel) for the management of various cancers including breast, prostate and lung.
Docetaxel 20mg/ml, 1ml injection, which is on National Contract from Accord Healthcare (Pty) Ltd, is currently unavailable. The docetaxel 20mg injection, will only be available at the end of April 2025. Docetaxel 80mg injection, paclitaxel 30mg and paclitaxel 100mg injections are all currently available.
In the interim, while docetaxel 20mg injection is unavailable, docetaxel 80mg injection or paclitaxel (30mg, 100mg) can be considered for use. For new patients for initiation on a taxane regimen for the management of breast or lung cancer, it is advised that paclitaxel be initiated during this period. Note it may be very risky and difficult to switch patients from one taxane to another mid-treatment and should only be considered in extreme circumstances as guided by an oncologist.